Once-Weekly Insulin Promising in Phase 3 Trial in Type 2 Diabetes
-
The investigational once-weekly insulin icodec (Novo Nordisk) significantly reduces A1c without increasing hypoglycemia in people with type 2 diabetes, the first Phase 3 data of such an insulin formulation suggest. The data are from one of six trials in the company's ONWARDS program.
-
@gurnur In ONWARDS 2, 526 adults with type 2 diabetes were randomized to switch from their current once- or twice-daily basal insulin to either once-weekly icodec or once-daily insulin degludec (Tresiba) for 26 weeks. The study was open-label, with a treat-to-glucose target of 80-130 mg/dL design.